Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,200 shares, an increase of 9.1% from the November 30th total of 1,100 shares. Based on an average daily volume of 6,200 shares, the […]
Humacyte (NASDAQ:HUMA – Free Report) had its price target cut by Benchmark from $16.00 to $15.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other brokerages also recently weighed in on HUMA. Piper Sandler lowered their price objective on shares […]
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 6,090,000 shares, a growth of 10.7% from the October 31st total of 5,500,000 shares. Based on an average daily trading volume, of 583,200 shares, the short-interest ratio […]
– Positive top line results from the V005 Phase 2/3 trial of the Human Acellular Vessel™ (HAV™) in vascular trauma repair – – BLA for an indication in vascular trauma planned to be filed with the FDA during the current quarter – - Conference call and live webcast at 4:30 p.m. ET today - DURHAM, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, t